Anti-Human Activin RIIA/B Reference Antibody (Bimagrumab, RUO) (HB949016)

Name: Anti-Human Activin RIIA/B Reference Antibody (Bimagrumab, RUO)
Brand: abinScience
SKU: HB949016
Price: 176 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.	HB949016
Description	Bimagrumab (HB949016) is a research-grade recombinant antibody targeting ACVR2. Produced in mammalian cells with native-like glycosylation. Highlights ●Research Grade — For PK/PD studies, assay development, and ADA research. ●Native Glycosylation — Mammalian expression ensures native-like patterns.
Species reactivity	Human
Applications	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Host species	Human
Isotype	IgG1-lambda
Expression system	Mammalian cells
Clonality	Monoclonal
Target	ACVR2, ACTRIIA, ACTR-IIA, Activin receptor type IIA, ACVR2A, Activin receptor type-2A, ACTR-IIB, Activin receptor type IIB, Activin receptor type-2B, ACVR2B
Endotoxin level	Please contact the lab for this information.
Purity	>95% purity as determined by SDS-PAGE.
Purification	Protein A/G purified from cell culture supernatant.
Accession	P27037 & Q13705
Form	Liquid
Storage buffer	0.01M PBS pH 7.4 Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Stability and Storage	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternate Names	BYM338, 1356922-05-8
Background	Bimagrumab is a monoclonal anti-ActRIIA/IIB antibody that targets ActRIIA and ActRIIB simultaneously. Native ActRIIA and ActRIIB are both mediators of signaling from several TGFβ superfamily members such as activins, myostatin, and GDF11. Hence, pan-blockade by Bimagrumab achieves greater effect than a monoclonal antibody against either receptor alone, i.e. monotherapy with anti-ActRIIA antibody or anti-ActRIIB antibody. Bimagrumab has been explored as a therapy for sporadic inclusion body myositis, primary sarcopenia, and muscle wasting associated with chronic obstructive pulmonary disease. • Activin A inhibits BMP-signaling by binding ACVR2A and ACVR2B., PMID:26047946 • BMPR2 inhibits activin and BMP signaling via wild-type ALK2., PMID:29739878 • ALK2/ALK3-BMPR2/ACVR2A Mediate BMP2-Induced Downregulation of Pentraxin 3 Expression in Human Granulosa-Lutein Cells., PMID:28977600 • Follicular localization of growth differentiation factor 8 and its receptors in normal and polycystic ovary syndrome ovaries., PMID:29409020
Note	For research use only. Not suitable for clinical or therapeutic use.

Images

SEC-HPLC

SEC-HPLC detection for Research Grade Bimagrumab.
Bioactivity

Detects ACVR2A in indirect ELISAs.
Flow Cytometry

Flow-cytometry using anti-human ACVR2A antibody. Hela cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human ACVR2A monoclonal antibody (Catalog HB949016, Yellow Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a a Goat Anti-Human IgG H&L Polyclonal Antibody, FITC (abinScience: HF690414) and cells analysed on a NovoCyte Flow Cytometer.
SDS-PAGE

SDS-PAGE for Research Grade Bimagrumab